Skip to main content

Advertisement

SpringerLink
Log in

The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

An Erratum to this article was published on 01 September 2015

Abstract

The new oral anticoagulants (NOACs) reduce stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), but dabigatran may increase risk of coronary ischemic events for unclear reasons. Thus, this study assessed the effects of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers in patients with non-valvular AF. Patients with non-valvular AF planned to begin treatment with NOACs were included. Seventeen patients were prescribed dabigatran and ten rivaroxaban. Platelet function (as assessed by multiple-electrode aggregometry, Impact-R shear-induced platelet deposition, P-selectin expression and plasma RANTES levels) and high-sensitivity C-reactive protein (hs-CRP) were measured at enrollment (prior to initiation of NOAC treatment) and at least 7 days into treatment with either dabigratran or rivaroxaban. Seventeen patients treated with dabigatran (mean age 69 ± 7 years, 35 % women, mean CHADS2 score 2.6 ± 1.2), and ten patients treated with rivaroxaban (mean age 73 ± 9 years, 20 % women, mean CHADS2 score 2.7 ± 1.6) completed the study. In both groups, there were no significant differences in platelet reactivity between the baseline and on-anticoagulant treatment time-points, as measured by each of the platelet-specific assays. There was a trend towards increased platelet reactivity in response to arachidonic acid from baseline to on-treatment in both groups, probably as a result of aspirin discontinuation in 33 % of patients. No significant differences were noted between baseline and on-treatment in hs-CRP in both anticoagulant groups. Treatment with dabigatran and rivaroxaban does not appear to be associated with changes in markers of platelet reactivity or systemic inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429

    Article  PubMed  Google Scholar 

  2. Fuster V, Ryden LE, Cannom DS et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:e269–e367

    Article  PubMed  Google Scholar 

  3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952

    Article  CAS  PubMed  Google Scholar 

  4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32:695–703

    Article  CAS  PubMed  Google Scholar 

  5. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB (2004) Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94:889–894

    Article  PubMed  Google Scholar 

  6. Frost L, Andersen LV, Vestergaard P, Husted S, Mortensen LS (2007) Trend in mortality after stroke with atrial fibrillation. Am J Med 120:47–53

    Article  PubMed  Google Scholar 

  7. Genovesi S, Vincenti A, Rossi E et al (2008) Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51:255–262

    Article  PubMed  Google Scholar 

  8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98:476–484

    Article  CAS  PubMed  Google Scholar 

  9. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988

    Article  CAS  PubMed  Google Scholar 

  10. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L (2008) Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 94:1607–1613

    Article  CAS  PubMed  Google Scholar 

  11. Mant J, Hobbs FD, Fletcher K et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 11(370):493–503

    Article  Google Scholar 

  12. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE (1999) Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 131:927–934

    Article  CAS  PubMed  Google Scholar 

  13. (1998) Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 279:1273–1277

  14. (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687–691

  15. Ezekowitz MD, Bridgers SL, James KE et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406–1412

    Article  CAS  PubMed  Google Scholar 

  16. (1990) Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 322:863–868

  17. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  18. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  19. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  20. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402

    Article  CAS  PubMed  Google Scholar 

  21. Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19

    Article  CAS  PubMed  Google Scholar 

  22. Christersson C, Johnell M, Siegbahn A (2010) The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. Thromb Res 126:e327–e333

    Article  CAS  PubMed  Google Scholar 

  23. Christersson C, Oldgren J, Wallentin L, Siegbahn A (2011) Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 270:215–223

    Article  CAS  PubMed  Google Scholar 

  24. Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856

    Article  CAS  PubMed  Google Scholar 

  25. Shenkman B, Savion N, Dardik R, Tamarin I, Varon D (2000) Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 99:353–361

    Article  CAS  PubMed  Google Scholar 

  26. Li Z, Delaney MK, O’Brien KA, Du X (2010) Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30:2341–2349

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Aggarwal A, Sobel BE, Schneider DJ (2002) Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13:161–165

    Article  CAS  PubMed  Google Scholar 

  28. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ (2006) Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 118:361–369

    Article  CAS  PubMed  Google Scholar 

  29. Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS (2006) Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost 95:441–446

    CAS  PubMed  Google Scholar 

  30. Wolzt M, Bostrom SL, Svensson M, Wahlander K, Grind M, Sarich TC (2003) Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol Haemost Thromb 33:68–74

    Article  CAS  PubMed  Google Scholar 

  31. Weitz JI, Hudoba M, Massel D et al (1990) Clot-bound thrombin is protected frominhibition by heparin-antithrombin III but is susceptible to inactivation byantithrombin III-independent inhibitors. J Clin Invest 86:385–391

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Farivar AS, Delgado MF, McCourtie AS et al (2006) Crosstalk between thrombosisand inflammation in lung reperfusion injury. Ann Thorac Surg 81:1061–1067

    Article  PubMed  Google Scholar 

  33. Erlich JH, Boyle EM, Labriola J et al (2000) Inhibition of the tissue factor-thrombinpathway limits infarct size after myocardial ischemia-reperfusion injury byreducing inflammation. Am J Pathol 157:1849–1862

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Chen B, Cheng Q, Yang K et al (2010) Thrombin mediates severe neurovascularinjury during ischemia. Stroke 41:2348–2352

    Article  CAS  PubMed  Google Scholar 

  35. Mattsson C, Sarich TC, Carlsson SC (2005) Mechanism of action of the oral directthrombin inhibitor ximelagatran. Semin Vasc Med 5:235–244

    Article  PubMed  Google Scholar 

  36. Marty I, Peclat V, Kirdaite G et al (2001) Amelioration of collagen-induced arthritis bythrombin inhibition. J Clin Invest 107:631–640

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Renda G, Malatesta G, Bucciarelli V, et al. Differential effects of the direct thrombin inhibitor dabigatran etexilate vs warfarin on platelet function. http://spo.escardio.org/eslides/view.aspx?eevtid=54&fp=5292

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Rabin Medical Center, Petah-Tikva, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Noa Zemer-Wassercug, Katia L. Orvin, Ariel Gutstein, Ehud Kadmon, Aviv Mager, Ran Kornowski & Eli L. Lev

  2. Department of Cardiology, Meir Medical Center, Kfar Saba, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Moti Haim

  3. The Felsenstein Medical Research Center, Rabin Medical Center, Petah-Tikva, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Dorit Leshem-Lev

  4. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Muthiah Vaduganathan

Authors
  1. Noa Zemer-Wassercug
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moti Haim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dorit Leshem-Lev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katia L. Orvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muthiah Vaduganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ariel Gutstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ehud Kadmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aviv Mager
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ran Kornowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eli L. Lev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eli L. Lev.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

Rabin Medical Center.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zemer-Wassercug, N., Haim, M., Leshem-Lev, D. et al. The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis 40, 340–346 (2015). https://doi.org/10.1007/s11239-015-1245-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1245-z

Keywords

Search

Navigation